Eli Lilly’s Legal Battle with Empower Raises Questions for the Compounding Pharmacy Market

Key Highlights of the Case

Eli Lilly has filed a lawsuit against Houston-based Empower Pharmacy, accusing it of producing and selling unauthorized versions of its blockbuster drugs Mounjaro and Zepbound. The case highlights growing tensions between pharmaceutical giants, compounding pharmacies, and regulators over drug safety, affordability, and market control in the multi-billion-dollar obesity and diabetes treatment space.

The Lawsuit

• Filed on April 1, 2025, in the District Court of New Jersey.
• Targets Empower Pharmacy for allegedly selling unauthorized tirzepatide formulations.
• Focus on injectable versions and Tirzepatide ODT (orally disintegrating tablet).

Eli Lilly’s Allegations

• Claims Empower’s drugs are “knockoffs” that mislead patients.
• Says the products bypass FDA approval, creating safety risks.
• Eli Lilly: “By selling Tirzepatide ODT, Empower is essentially conducting a mass testing experiment on consumers.”

Empower Pharmacy’s Defense

• Denies producing copies of Lilly’s drugs.
• Operates as an FDA-registered 503B outsourcing facility.
• Argues lawsuit is about control, not safety.
• Statement: “Over a hundred million Americans cannot access or afford the name-brand version of these therapies. We’re filling that gap, legally, responsibly.”

FDA Involvement

• On April 2, 2025, FDA issued a warning letter to Empower.
• Found failures to meet 503B outsourcing conditions.
• FDA clarified: 503B registration ≠ FDA approval of compounded drugs.

Background: Shortage & Compounding

• Mounjaro and Zepbound saw surging demand in 2024, causing shortages.
• FDA temporarily allowed compounded versions during shortage.
• Shortage resolved in 2025 → FDA restricted compounding again.

Industry Context & Market Growth

• The dispute highlights the rapid growth of the compounding pharmacy market.
• The global compounding pharmacy market was valued at USD 13.19 billion in 2023 and is projected to reach USD 22.91 billion by 2034, growing at a CAGR of 5.15%.
  • Eli Lilly has also sued Strive Pharmacy for similar claims.
  • Compounding pharmacies earlier sued FDA after shortage status was lifted.
  • Debate reflects drugmaker IP rights vs. patient access.

Market Position and Financials 2026

What’s Next

• Empower has until April 24, 2025, to respond.
• Case outcome could impact the future of compounding pharmacies in the U.S. drug market.
• Obesity and diabetes drugs remain a multi-billion-dollar business battleground.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com